2-(3'-nitrophenyl)-7-methyl-1H-benzo[d]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(3'-nitrophenyl)-7-methyl-1H-benzo[d]imidazole
• 英文别名: 7-methyl-2-(3-nitrophenyl)-1H-benzo[d]imidazole；4-methyl-2-(3-nitrophenyl)-1H-benzimidazole
• 化学式: C₁₄H₁₁N₃O₂
• 分子量: 253.26
• InChiKey: YXCMZZUISFFLOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3'-nitrophenyl)-7-methyl-1H-benzo[d]imidazole 在 10% palladium on activated carbon 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 3.0h， 生成 3-(4-methyl-1H-benzimidazol-2-yl)aniline
  参考文献：
  名称：

  Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae

  摘要：

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.

  DOI：

  10.1021/jm1008083
• 作为产物：
  描述：

  2,3-二氨基甲苯 在 吡啶 、 4-二甲氨基吡啶 、 对甲苯磺酸 作用下， 以 对二甲苯 为溶剂， 反应 18.25h， 生成 2-(3'-nitrophenyl)-7-methyl-1H-benzo[d]imidazole
  参考文献：
  名称：

  Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae

  摘要：

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.

  DOI：

  10.1021/jm1008083

文献信息

• Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors
  作者：Antonio Laghezza、Grazia Luisi、Alessia Caradonna、Antonella Di Pizio、Luca Piemontese、Fulvio Loiodice、Mariangela Agamennone、Paolo Tortorella

  DOI：10.1016/j.bmc.2019.115257

  日期：2020.2

  structure-activity relationship (SAR) of the benzimidazole scaffold was explored by synthesis of several analogues whose inhibition activity was tested with enzyme inhibition assays. By performing the molecular simplification approach, we disclosed different sets of single-digit micromolar inhibitors of MMP-2, with up to a ten-fold increase in inhibitory activity and ameliorated selectivity towards off-target

  基质金属蛋白酶（MMPs）是锌依赖性内切蛋白酶的一大家族，已知在肿瘤的进展和侵袭性中起多种调节作用。多年来，这鼓励了针对抗癌治疗的MMP，尤其是MMP-2的方法。由于在临床上出现毒性和其他缺陷，基于（假）肽支架组装的非特异性锌结合基（ZBGs）的MMP抑制剂的早期世代已被中止，这为有或没有锌螯合剂部分的抑制剂铺平了道路。结合催化锌离子。在本文中，我们继续寻找新的非锌结合性MMP-2抑制剂：利用先前鉴定的化合物，开展了虚拟筛选（VS）运动，并导致了新一类配体的鉴定。通过合成几种类似物来探索苯并咪唑支架的构效关系（SAR），这些类似物的抑制活性已通过酶抑制试验进行了测试。通过执行分子简化方法，我们公开了不同组的MMP-2单位数微摩尔抑制剂，与所选先导化合物相比，抑制活性和对脱靶MMP-8的选择性提高了多达十倍。对具有对接的特权结构的MMP-2配合物进行的分子动力学计算证实，分析的抑制剂可避免靶
• Synthesis, α-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles
  作者：Muhammad Taha、Nor Hadiani Ismail、Syahrul Imran、Muhammad Helmi Mohamad、Abdul Wadood、Fazal Rahim、Syed Muhammad Saad、Ashfaq ur Rehman、Khalid Mohammed Khan

  DOI：10.1016/j.bioorg.2016.02.004

  日期：2016.4

  Benzimidazole analogs 1-27 were synthesized, characterized by EI-MS and H-1 NMR and their alpha-glucosidase inhibitory activities were found out experimentally. Compound 25, 19, 10 and 20 have best inhibitory activities with IC50 values 5.30 +/- 0.10, 16.10 +/- 0.10, 25.36 +/- 0.14 and 29.75 +/- 0.19 respectively against alpha-glucosidase. Compound 6 and 12 has no inhibitory activity against alpha-glucosidase enzyme among the series. Further studies showed that the compounds are not showing any cytotoxicity effect. The docking studies of the compounds as well as the experimental activities of the compounds correlated well. From the molecular docking studies, it was observed that the top ranked conformation of all the compounds fit well in the active site of the homology model of alpha-glucosidase. (C) 2016 Elsevier Inc. All rights reserved.
• Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against <i>Chlamydia pneumoniae</i>
  作者：Leena Keurulainen、Olli Salin、Antti Siiskonen、Jan Marco Kern、Joni Alvesalo、Paula Kiuru、Matthias Maass、Jari Yli-Kauhaluoma、Pia Vuorela

  DOI：10.1021/jm1008083

  日期：2010.11.11

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.